Medical Access in Oman

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The Sultanate's Law on the Control of Narcotic Drugs and Psychotropic Substances (and subsequent Royal Decree amendments) criminalizes unauthorized possession, supply, cultivation and trafficking of substances and plants listed in its schedules; penalties include lengthy imprisonment and large fines for non‑authorized activity. [1]Law on the Control of Narcotic Drugs and Psychotropic Substances No. 28 of 2000

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Oman enforces strict penalties for importation, trafficking, possession and distribution of psychotropic substances; law and public prosecution guidance emphasize severe sanctions and active enforcement. [1]Law on the Control of Narcotic Drugs and Psychotropic Substances No. 28 of 2000

There is no publicly available evidence of national marketing approval or routine clinical reimbursement for esketamine (Spravato®) in Oman as of the most recent official legislative and regulatory information. Oman’s narcotics/psychotropic control law and implementing rules require institutions to obtain licences/permit lists from national regulators (Directorate General of Pharmaceutical Affairs and Drug Control / Ministry-level authorities) to handle controlled narcotics and psychotropic medicines, which means an entity wishing to supply or use esketamine would need formal registration and narcotics handling authorization prior to use. [1]Royal Decree 24/2023 (amending narcotics law) [2]Law on the Control of Narcotic Drugs and Psychotropic Substances No. 28 of 2000

Practical implication: without clear Ministry of Health/registration list evidence showing Spravato or esketamine registration in Oman, esketamine would currently only be accessible through an authorized clinical trial or via a formally approved import/registration process and licensed narcotics handling procedures. There is no indication of routine public reimbursement or documented nationwide private insurance coverage for esketamine in Oman in public sources examined.

Ketamine (injectable) is a recognized and widely used anaesthetic and analgesic agent in clinical practice internationally and within the Gulf region, and Oman’s regulatory framework provides for licenced medical institutions to maintain lists of permitted narcotics/psychotropic substances for legitimate clinical use. Oman’s narcotics law requires institutions to obtain licences and to keep controlled drugs in secure storage, indicating a regulated pathway for legitimate medical use of controlled anesthetic agents like ketamine. [1]Law on the Control of Narcotic Drugs and Psychotropic Substances No. 28 of 2000 [2]Regional guidance on institutional licensing and narcotics handling

Detailed context and reimbursement implications:
- Regulatory/administrative control: The Directorate General of Pharmaceutical Affairs and Drug Control (and related Ministry/regulatory bodies) governs licensing, importation and institutional lists for controlled drugs; facilities must hold appropriate licences/permits to procure and administer controlled anesthetics. [3]Royal Decree 24/2023 (amending narcotics law)
- Clinical use: Ketamine injectable is an established anesthetic/analgesic used in hospitals and emergency care. In practice, Omani public hospitals (Ministry of Health and other government hospitals) and private hospitals that are licensed to handle controlled substances will administer ketamine for approved indications (e.g., induction/maintenance of anesthesia, procedural sedation, acute pain management) under standard hospital formularies and narcotics handling rules. (International and regional drug monographs describe ketamine as an approved anesthetic; national hospital formularies operate under the licensing regime cited above.) [1]Law on the Control of Narcotic Drugs and Psychotropic Substances No. 28 of 2000
- Psychiatric/off‑label indications and reimbursement: Ketamine is not internationally registered for routine psychiatric indications (e.g., as a licensed antidepressant in oral/compounded forms), and major regulators (e.g., FDA) warn about unapproved compounded ketamine for psychiatric use; similarly in Oman there is no public evidence of an established, reimbursed pathway for ketamine for psychiatric indications. Any off‑label psychiatric use would be subject to institutional clinical governance, local regulatory approval, and insurer policies; routine public reimbursement for psychiatric ketamine (outside established anesthetic uses) is not evidenced in public sources. [4]FDA guidance on compounded ketamine products

Operational note: Hospitals and licensed clinics wishing to use ketamine must comply with national narcotics licensing, secure storage/recordkeeping, and importation/registration requirements; reimbursement depends on whether the treatment falls under standard hospital service tariffs or is an explicitly covered indication by the payer (public or private insurer) — no publicly available national policy documents indicate routine reimbursement for psychiatric ketamine programs in Oman.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Oman’s narcotics statute and implementing decrees criminalize unauthorized importation, possession, supply and manufacture of psychotropic substances; DMT and plant preparations containing DMT would fall under those controlled categories in the absence of an explicit authorised medical program. [1]Law on the Control of Narcotic Drugs and Psychotropic Substances No. 28 of 2000

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The national law criminalizes plants and synthetic psychotropic agents not specifically authorized for medical use; 5‑MeO‑DMT has no documented authorized medical program or routine clinical availability in Oman. [1]Law on the Control of Narcotic Drugs and Psychotropic Substances No. 28 of 2000

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public evidence of authorized ibogaine medical programs or licensing in Oman, and the narcotics law’s schedules and enforcement provisions apply to such psychotropic substances. [1]Law on the Control of Narcotic Drugs and Psychotropic Substances No. 28 of 2000

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Preparations containing DMT (such as ayahuasca) fall under psychotropic/plant controls in the absence of explicit regulatory exemption; Oman’s legal framework criminalizes cultivation/possession/distribution of listed plants and psychotropic substances. [1]Law on the Control of Narcotic Drugs and Psychotropic Substances No. 28 of 2000

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Cacti or extracts containing mescaline are subject to the same narcotics/psychotropic controls and criminal penalties absent a formal medical authorization. [1]Law on the Control of Narcotic Drugs and Psychotropic Substances No. 28 of 2000

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Synthetic phenethylamines (the 2C family) are covered by Oman’s psychotropic/narcotic legislation and are subject to criminal penalties for unauthorized possession, supply or trafficking. [1]Law on the Control of Narcotic Drugs and Psychotropic Substances No. 28 of 2000